The aim of this study was to combine breast MRI-derived biomarkers with clinicalpathological parameters to identify patients who truly need an Oncotype DX Breast Recurrence Score® (ODXRS) genomic assay, currently used to predict the benefit of adjuvant chemotherapy in ER-positive/HER2-negative early breast cancer, with the ultimate goal of customizing therapeutic decisions while reducing healthcare costs. Patients who underwent a preoperative multiparametric MRI of the breast and ODXRS tumor profiling were retrospectively included in this study. Imaging sets were evaluated independently by two breast radiologists and classified according to the 2013 American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) lexicon. In a second step of the study, a combined oncologic and radiologic assessment based on clinical-pathological and radiological data was performed, in order to identify patients who may need adjuvant chemotherapy. Results were correlated with risk levels expressed by ODXRS, using the decision made on the basis of the ODXRS test as a gold standard. Theχ2 test was used to evaluate associations between categorical variables, and significant ones were further investigated using logistic regression analyses. A total of 58 luminal-like, early-stage breast cancers were included. A positive correlation was found between ODXRS and tumor size (p = 0.003), staging (p = 0.001) and grading(p=0.005),andbetweenBI-RADScategoriesandODXRS(p<0.05forbothreaders),the latter being confirmed at multivariate regression analysis. Moreover, BI-RADS categories proved to be positive predictors of the therapeutic decision taken after performing an ODXRS assay. A statistically significant association was also found between the therapeutic decision based on the ODXRS and the results of combined onco-radiologic assessment (p < 0.001). Our study suggests that there is a correlation between BI-RADS categories at MRI and ODXRS and that a combined onco-radiological assessment may predict the decision made on the basis of the results of ODXRS genomic test.

Precision medicine in breast cancer: do MRI biomarkers identify patients who truly benefit from the Oncotype DX Recurrence Score® Test? / Galati, Francesca; Magri, Valentina; Moffa, Giuliana; Rizzo, Veronica; Botticelli, Andrea; Cortesi, Enrico; Pediconi, Federica. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:11(2022). [10.3390/diagnostics12112730]

Precision medicine in breast cancer: do MRI biomarkers identify patients who truly benefit from the Oncotype DX Recurrence Score® Test?

Francesca Galati
Co-primo
;
Valentina Magri
Co-primo
;
Giuliana Moffa;Veronica Rizzo;Andrea Botticelli;Enrico Cortesi
Penultimo
;
Federica Pediconi
Ultimo
2022

Abstract

The aim of this study was to combine breast MRI-derived biomarkers with clinicalpathological parameters to identify patients who truly need an Oncotype DX Breast Recurrence Score® (ODXRS) genomic assay, currently used to predict the benefit of adjuvant chemotherapy in ER-positive/HER2-negative early breast cancer, with the ultimate goal of customizing therapeutic decisions while reducing healthcare costs. Patients who underwent a preoperative multiparametric MRI of the breast and ODXRS tumor profiling were retrospectively included in this study. Imaging sets were evaluated independently by two breast radiologists and classified according to the 2013 American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) lexicon. In a second step of the study, a combined oncologic and radiologic assessment based on clinical-pathological and radiological data was performed, in order to identify patients who may need adjuvant chemotherapy. Results were correlated with risk levels expressed by ODXRS, using the decision made on the basis of the ODXRS test as a gold standard. Theχ2 test was used to evaluate associations between categorical variables, and significant ones were further investigated using logistic regression analyses. A total of 58 luminal-like, early-stage breast cancers were included. A positive correlation was found between ODXRS and tumor size (p = 0.003), staging (p = 0.001) and grading(p=0.005),andbetweenBI-RADScategoriesandODXRS(p<0.05forbothreaders),the latter being confirmed at multivariate regression analysis. Moreover, BI-RADS categories proved to be positive predictors of the therapeutic decision taken after performing an ODXRS assay. A statistically significant association was also found between the therapeutic decision based on the ODXRS and the results of combined onco-radiologic assessment (p < 0.001). Our study suggests that there is a correlation between BI-RADS categories at MRI and ODXRS and that a combined onco-radiological assessment may predict the decision made on the basis of the results of ODXRS genomic test.
early breast cancer; multiparametric MRI; MRI biomarkers; oncotype DX recurrence score; genomic assays; adjuvant therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Precision medicine in breast cancer: do MRI biomarkers identify patients who truly benefit from the Oncotype DX Recurrence Score® Test? / Galati, Francesca; Magri, Valentina; Moffa, Giuliana; Rizzo, Veronica; Botticelli, Andrea; Cortesi, Enrico; Pediconi, Federica. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:11(2022). [10.3390/diagnostics12112730]
File allegati a questo prodotto
File Dimensione Formato  
Galati_Precision-medicine_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 866.63 kB
Formato Adobe PDF
866.63 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1658907
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact